Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Sep 19 - Sep 24
Triple Agonist Versus Dual Agonist Therapy Tirzepatide is an approved dual GIP/GLP-1 receptor agonist, while retatrutide is an investigational triple agonist that also activates the glucagon receptor [1], [13]
Females had higher LVEF, BMI, CRP, physical limitations, and worse heart failure symptoms and a lower likelihood of having prior histories of coronary heart disease or atrial fibrillation and consuming sodium-glucose cotransporter-2 inhibitors (SGLT2i), angiotensin-converting enzyme (ACE) inhibitors, or angiotensin II receptor blockers (ARB) compared to men
Tirzepatide's dual activation may increase GI side effects, particularly during titration
SUMOUNT-4 demonstrated that continued treatment is necessary to maintain weight loss, with significant regain occurring after discontinuation
Endocrine Connections, 4:50-57
US$ 22.95
US$ 23.78
US$ 28.70
US$ 24.91
US$ 25.55
